Date: 2017-12-21
Type of
information: Completion of the trial
phase:
Announcement:
Company: Sanifit (Spain - Switzerland)
Product: SNF472 - hexasodium phytate
Action
mechanism:
- SNF472 (hexasodium phytate) selectively blocks the pathological cardiovascular calcification progression. The FDA and the EMA have granted SNF472 orphan drug designation for the treatment of calciphylaxis. Preclinical models have already demonstrated that SNF472 reduces the progression of calcium deposition in blood vessels and cardiac tissue.
Disease: calciphylaxis
Therapeutic
area: Rare diseases - Cardiovascular diseases
Country: UK, USA
Trial
details:
Latest
news:
- • On December 21, 2017, Sanifit announced that the last patient's last visit occurred in the Phase II study of SNF472, its lead candidate for the treatment of calciphylaxis (calcific uraemic arteriolopathy, CUA) . The trial was done in collaboration with internationally recognised calciphylaxis experts in the US, Spain, Germany and the UK. Sanifit expect to present and publish the data from the trial on healing of skin ulcers in early 2018.
- In addition to the calciphylaxis program, SNF472 is being developed for the reduction in progression of cardiovascular calcification in dialysis patients. A Phase IIb trial is currently underway for this separate indication.
Is
general: Yes